Percutaneous ultrasound-guided celiac plexus neurolysis in advanced upper abdominal cancer pain  by Tadros, Mary Y. & Elia, Remon Zaher
The Egyptian Journal of Radiology and Nuclear Medicine (2015) 46, 993–998Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLEPercutaneous ultrasound-guided celiac plexus
neurolysis in advanced upper abdominal cancer pain* Corresponding author. Tel.: +20 01223696051.
E-mail address: myaftah@yahoo.com (M.Y. Tadros).
Peer review under responsibility of Egyptian Society of Radiology and
Nuclear Medicine.
http://dx.doi.org/10.1016/j.ejrnm.2015.06.009
0378-603X  2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Mary Y. Tadros *, Remon Zaher EliaRadiology Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptReceived 6 April 2015; accepted 15 June 2015
Available online 4 July 2015KEYWORDS
Celiac plexus neurolysis
(CPN);
Visual analog scale (VAS);
Hepatocellular carcinoma
(HCC);
Endoscopic ultrasound
(EUS)Abstract Back ground: The alleviation of suffering in cancer patients is universally acknowledged
as a cardinal goal of medical care. Celiac plexuses neurolysis is an effective technique in decreasing
pain severity in patients suffering from upper abdominal cancer as it decreases analgesic require-
ments.
Objective: This study aims to evaluate the efﬁcacy of ultrasound-guided celiac plexus neurolysis
(CPN) in controlling pain in patients with upper abdominal cancer pain.
Materials & Methods: Ultrasound-guided CPN was done for 21 adult patients suffering from
upper abdominal cancer pain using ethanol (50%) as a neurolytic agent. Visual analog scale
(VAS) score was used to assess the degree of pain relief immediately after injection at 1 week,
1 month and 3 months post-neurolysis.
Results: Marked decrease of pain severity in all patients was noted as a sharp fall of the VAS score
in the 1st day after CPN with relatively stationary course for 3 months. Baseline VAS score was
9.1 ± 0.85. One day after CPN, pain severity decreased markedly to 1.4 ± 0.71. One week after
CPN the decrease in pain severity was maintained at the same level 1.6 ± 0.89. One month after
CPN the decrease in pain severity maintained at the same level 2 ± 0.79 .3 months after CPN, pain
severity decreased signiﬁcantly to 2.3 ± 1.02.
Conclusion: Ultrasound-guided CPN is an effective method for reducing pain of upper abdominal
cancer.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The celiac plexus is a dense network of autonomic nerves that
lies anterior to the aorta and the crus of the diaphragm at L1level (1). Methods to administer neurolytic agents to the celiac
ganglion included surgery, CT-guided injection, percutaneous
ultrasonography, ﬂuoroscopy or endoscopic ultrasonography
-guided (EUS) approaches (2). The main disadvantages for
the use of CT and ﬂuoroscopy are that it does not provide real
time imaging, it carries the risk of exposure to hazards of
radiation, it is time-consuming, and expensive and the use of
endoscopic ultrasound requires special equipment and
formal training in gastroenterology (3). Ultrasound (US) is a
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allows the identiﬁcation of soft tissues, vessels, and nerves,
without exposing patients or medical personnel to radiation.
2. Materials and methods
2.1. Subjects
The study was done in specialized private centers in Cairo dur-
ing the period from November 2013 to December 2014. The
study was carried out on 21 adult patients suffering from
abdominal pain due to upper abdominal cancer (Table 1).
The technique was successfully performed in 20 patients of
whom 18 (90%) were males and 2 (10%) were females with
mean age 55.7 ± 4.83 (Table 2) via paramedian needle entry
technique (95.2%). Only one case failed (4.8%) due to colonic
distension obscuring the celiac trunk. CT-guided CPN was
successfully done for this patient via anterior approach
technique.
Inclusion criteria
 Abdominal pain due to upper abdominal cancer.
 Pain not controlled by WHO analgesic step ladder.
 Patients suffering from side effects of analgesic drugs.
Exclusion criteria
 Patient refusal.
 Patients with coagulopathy.
 Patients with colonic gas distension.
2.2. Methods
All patients were subjected to history taking, general examina-
tion, abdominal ultrasound, CT abdomen, chest X-ray, coag-
ulation proﬁle, stoppage of pain medications overnight,
training on breath holding, informing about complications
and hospital stay time.Table 1 Descriptive statistics of the causes of abdominal pain.
Cause of pain Frequency Percent (%)
HCC 9 45
Pancreatic carcinoma 8 40
Lymphoma 2 10
GB adenocarcinoma 1 5
Table 2 Descriptive statistics of sociodemographic data.
Frequency Percent (%)
Sex Male 18 90
Female 2 10
Age 40–50 years 1 5
51–60 years 15 75
61–70 years 4 20
Minimum (48 years) Maxi (66 years) Mean ± SD
55.7 ± 4.83This procedure was done with the patient in the supine
position while fasting for 8 h. IV cannula size 18 G was
inserted and all patients received an intravenous ringer solu-
tion of 1000 ml. Standard monitors were used including auto-
matic cuff blood pressure, pulse oximeter, ECG. Baseline
values for mean arterial blood pressure, heart rate, and oxygen
saturation were taken. A 3–5 MHz convex transducer was
applied over epigastric area to deﬁne the common celiac trunk
at its origin from the aorta and at its division into hepatic and
splenic branches. After sterilization, subcutaneous anesthesia
with Lidocaine 2% was done and a 22-gauge Chiba needle
was introduced into the epigastrium via paramedian approach
to the transversely placed ultrasound transducer. Under sono-
graphic guidance, the tip of the needle was advanced into the
right lateral or the left lateral area of the celiac trunk (unilat-
eral or bilateral). Once the tip of the needle was correctly posi-
tioned, suction was applied to conﬁrm that the needle tip is not
inside a blood vessel, and a ‘‘prognostic block’’ performed by
injecting a local anesthetic (9 ml of Lidocaine 2%) for the
enforcement of a diagnostic celiac plexus block. 10 min after
successful prognostic block, 15 ml of 50% ethanol was injected
under US guidance. Ethanol appears echogenic in ultrasound.
Maximum ﬁlling of the retro pancreatic space with ethanol is
an indication of sufﬁcient neurolysis. Before the needle was
removed, 3 ml of Lidocaine 2% was injected to diminish irrita-
tion by ethanol. The patient stayed at the hospital for 4 h
under surveillance.
Patients were asked to grade the pain using the visual
analog scale (VAS) score (Fig. 1) for assessment of the degree
of pain relief. The assessment ranges from 0 (no pain) to 10
(severe pain). VAS was scored immediately after injection,
1 week, 1 month and 3 months post-neurolysis. Analgesic
requirements and complications were documented.
Complications observed were postural hypotension and
transient diarrhea.
2.3. Statistical methods
Statistical analysis was done by personal computer and statis-
tical package SPSS version 11. Two types of statistics were
done: descriptive statistics: e.g. percentage (%), mean (x), stan-
dard deviation (SD) and range. Analytic statistics: e.g. P-value
of <0.05 was considered statistically signiﬁcant.
3. Results
Marked decrease in pain severity in all patients was noted as a
sharp fall of the VAS score in the 1st day after CPN with rel-
atively stationary course for 3 months. Baseline VAS score was
9.1 ± 0.85. One day after CPN, pain severity decreased mark-
edly to 1.4 ± 0.71, one week after CPN the decrease in pain
severity maintained at the same level 1.6 ± 0.89 (Fig. 3), one
month after CPN the decrease in pain severity maintained atFig. 1 Visual analog scale.
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Fig. 2 Changes in the VAS score over time.
Percutaneous ultrasound-guided celiac plexus neurolysis 995the same level 2 ± 0.79 and 3 months after CPN pain severity
still decreased signiﬁcantly to 2.3 ± 1.02 (Fig. 4). The decrease
in pain severity at its average before and at different sequences
after CPN recorded highly signiﬁcant statistical difference
P value < 0.001 (Table 3) (Fig. 2).
According to analgesic drug consumption, it decreased sig-
niﬁcantly for three months after CPN. After one week, all
patients stopped opioids and 3 patients (15%) continued on
NSAIDS. While after three months, 8 patients (40%) contin-
ued on NSAIDS and 3 patients only (15%) took opioids again
but with lesser dose than the preblock doses (Table 4).
No major complications occurred, however local irritant
pain occurred in 12 patients (60%), hypotension occurred after
CPN in 4 patients (20%) who all responded to I.V ﬂuid ther-
apy while diarrhea occurred in 10 patients (50%) after CPN
and all responded to I.V ﬂuid therapy & Diosmectite sachets
(Table 5).
4. Discussion
Celiac plexus neurolysis is an interventional technique utilized
for the treatment of abdomino-visceral pain from upper
abdominal cancer. In gastrointestinal (GI) malignancies, com-
pression, invasion, or distension of visceral structures results in
a poorly localized noxious pain. All systemic analgesics (opioid
and nonopioid) may fail to provide adequate control of cancer
pain. Celiac plexus neurolysis (CPN) can be employed for pain
originating from the liver, pancreas & upper GI malignancies.(a)
Fig. 3(a and b) Male patient, 60 years old with cirrhotic liver and inﬁl
seen occupying the right hepatic lobe (blue arrow). The celiac trunk
Analgesics: Tramadol ampule once daily and Morphin tablet twice daIn this study, we used US-guided technique which was used
by several studies as Bhatnagar et al. (4) who performed celiac
plexus neurolysis under US guidance and stated that it offers
many advantages over the other procedures proposed as it
allows observation of the entire procedure on a video monitor
in real time. The US-guided procedure exposes neither patient
nor physician to unnecessary radiation, and is also less time-
consuming.
Gofeld (5) performed CPN under US guidance with similar
conclusion. Siddaiah and Sardesai (6) mentioned that US-
guided CPN is simple, inexpensive and (in contrast to the
EUS-guided CPN) does not require special equipment or for-
mal training in gastroenterology. Marcy et al. (7) concluded
that ultrasound guidance is safe and effective and should be
attempted for celiac plexus block whenever possible it almost
completely eliminates the risk of inadvertent injection of etha-
nol into vascular or intradural structures. Wang et al. (8) said
that the disadvantages of the ultrasound-guided CPN tech-
nique are as follows: ﬁrstly, ultrasound is not able to display
the pancreas and other retroperitoneal structures as clearly
as CT; secondly, the anatomic display varies from one opera-
tor of the ultrasound to another depending on their skills and
experience.
As regards anterior approach we found it more comfortable
with patient in the supine position. That comes in agreement
with Bhatnagar et al. (3) who performed CPN through ante-
rior approach and stated that patient is more comfortable
because this is understandable in the terminally ill patients
where the goal of the interventional palliation is a simple tech-
nique with minimal discomfort. Marcy et al. (7) performed
anterior celiac plexus block and proposed that the anterior
approach to percutaneous celiac ganglia is an easy, less inva-
sive and safely performed procedure with a high success rate.
Akhan et al. (9) stated that the major advantage of the anterior
approach is the reduced risk of neurologic complications
because the tip of the needle is anterior to the spinal arteries
and spinal canal. Narouze and Gruber (1) believed that the
most important advantage of the anterior approach is decreas-
ing or even eliminating the potential risk of paraplegia with
CPN.
Approaches and methods used to place the needle are either
single midline, single unilateral or bilateral para median on(b)
trative hepatocellular carcinoma. CT images (a) Inﬁltrative HCC is
(yellow arrow). (b) The tumor invades the right posterior PV.
ily. Pain degree by VAS (before CPN): 9/10.
(c) (d) 
(e) (f)
Fig. 3(c–f) After ultrasound-guided CPN was done: (c) Color Doppler study showing the celiac trunk. (d) The needle (yellow arrow) was
introduced through the left hepatic lobe. (e) Then, the needle crossed the hepatic artery (yellow arrow) till it reached the right celiac
ganglion. (f) Ethanol injection into the right celiac ganglion that appeared echogenic. There is difference in echogenicity between the right
(yellow arrow) and left (blue arrow) celiac ganglions. Right ganglion neurolysis was done using 12 mL Lidocaine 2% and 15 mL ethanol
50%. Pain degree after CPN (By VAS); immediately after CPN: 3/10, 1 week after CPN: 1/10, 1 month after CPN: 2/10 and 3 months
after CPN: 2/10. Analgesic requirements after CPN: 2 days after CPN: the patient had stopped Morphin. Only, Tramadol tablet was taken
once daily for 5 months.
996 M.Y. Tadros, R.Z. Eliaboth sides of celiac trunk. In the present study we used single
unilateral approach in 90% of patients, while bilateral
approach was done in 10% of patient as pain was not relieved
by single approach. A similar study reported that bilateral nee-
dles might be placed if there is not a satisfactory pain relief
using the unilateral approach by Rana et al. (10). A previous
study that performed CPN utilizing ultrasound-guided CPN
with bilateral paramedian needle entry technique showed high
success by Bhatnagar et al. (4) while another study stated that
bilateral CPN is more effective and is safe than central CPN by
Sahai et al. (11). Few complications, and overall good success
rate were reported in Caratozzolo et al. (12). Fugere and Lewis
(13) stated that with the same approach smaller dose of
neurolytic agent was required.
For CPN, 50–100% Alcohol or Phenol 10% concentration
was utilized. Phenol has the advantage of being painless with a
similar effectiveness; however, it has high viscosity & short
duration of block. Ethanol has longer duration of block, but
more painful. 20–50 mL of ethanol in concentrations of
50–100% is the most commonly used neurolytic agent inclinical practice (14). In our study, US-guided CPN was done
with injection of 15–30 mL of 50% ethanol. There was good
pain relief for 3 months for all patients. Bhatnagar et al. (3)
performed US-guided CPN for 20 patients with 15–20 mL of
50% ethanol injected bilaterally. They reported successful
CPN for all patients with good pain relief for 2 months.
Romanelli et al. (15) injected 15–40 mL of 50% Alcohol unilat-
erally. Pain was relieved in 92% (totally 61%, partially 31%)
of patients, and unchanged in 8%. However, Marcy et al. (7)
performed celiac plexus block (30 mL ethanol 99%) with pain
relief obtained in 79% of the patients which is less than our
results. As regards the technical success rate; in our study,
the technical success rate was 95.2%. US-guided CPN failed
in 1 patient (4.8%) due to marked colonic distension obscuring
the celiac trunk. Bhatnagar et al. (3) performed US-guided
CPN for 22 patients with technical success rate 91%. Marcy
et al. (7) performed celiac plexus block under CT and
ultrasound-guidance anterior approach single midline injec-
tion. The technical success rate was 100% for CT guidance
and 93% for ultrasound guidance.
(a) (b)                                      (c)
Fig. 4(a–c) Male patient, 64 years old, with cancer tail of pancreas and multiple hepatic deposits. CT scan (a) Shows hypodense poorly-
enhancing pancreatic tail mass (yellow arrow) with multiple hepatic deposits (blue arrows). (b) Multiple hepatic deposits (blue arrows). (c)
Shows the celiac trunk (yellow arrow). Analgesics: Tramadol tablets twice daily, Morphin tablet once daily and Nalophene ampule once
daily. Pain degree by VAS (Before CPN): 10/10.
(d) (e) (f)
Fig. 4(d–f) After ultrasound-guided CPN was done: (d) Color Doppler shows the celiac trunk (yellow arrow). (e) The needle crosses the
left hepatic lobe toward the right celiac ganglion (yellow arrow). (f) Ethanol spread at the right celiac ganglion that appears echogenic
(yellow arrow). Right ganglion neurolysis was done using 12 mL Lidocaine 2% and 15 mL ethanol 50%. Pain degree after CPN (By VAS);
immediately after CPN: 2/10, 1 week after CPN: 1/10, 1 month after CPN: 1/10 and 3 months after CPN: 3/10. Analgesic requirements
after CPN: 3 days after CPN, the patient had stopped opioids. Only, Paramol tablets were taken twice daily for 4 months.
Table 3 Pre- and post-intervention VAS score. Baseline VAS,
pain degree before CPN; D1, one day after CPN; W1, one week
after CPN; M1, one month after CPN; M3, three months after
CPN.
Score ± SD Parameter
9.1 ± 0.85 Baseline VAS
1.4 ± 0.71 D1 VAS
1.6 ± 0.89 W1 VAS
2 ± 0.79 M1 VAS
2.3 ± 1.02 M3 VAS
<0.001 P value
Table 4 Descriptive statistics of analgesic intake before and
after US-guided CPN.
Before After week After month After 3 months
No % No % No % No %
Opioids 20 100 0 0 0 0 3 15
NSAIDS 20 100 3 15 5 25 8 40
Percutaneous ultrasound-guided celiac plexus neurolysis 997In our study the degree of pain relief was signiﬁcantly
decreased in their VAS score and opioid consumption. These
results were similar to Bhatnagar et al. (3) who performed
US-guided CPN. They reported VAS score at the preblock
stage 9.10 ± 0.85. One day after CPN, VAS score markedly
decreased to 1.2 ± 1.02. 2 months after CPN, pain scoreshad decreased to 2.10 ± 0.79 (P< 0.001). Marcy et al. (7) also
performed US-guided CPN with the preblock VAS score
9.4 ± 0.7. They stated that the VAS score decreased sharply
to 1.3 ± 0.8 at the 1st day after neurolysis. 3 months later,
VAS score was 3.9 ± 1.2.
No major complications were recorded in our study similar
to Bhatnagar et al. (3) who stated that; hypotension occurred
in 15% of patients, diarrhea occurred in 55% of patients, and
pain at site of injection in 85% of his group of study and we
Table 5 Descriptive statistics of complications.
The studied group N= 20
Complications No %
No complications 4 20
Irritant pain at the site of injection 12 60
Transient diarrhea 10 50
Postural hypotension 4 20
998 M.Y. Tadros, R.Z. Eliacome in agreement with Alshab et al. (16) who reported that
transient diarrhea occurred in 65%, hypotension occurred in
52% and local pain at the injection site occurred in 40%.
5. Conclusion
Ultrasound-guided celiac plexus neurolysis technique is a safe
effective procedure in decreasing pain severity in patients
suffering from upper abdominal cancer with no major
complications and high success rates.
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